A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castration-resistant prostate cancer (mCRPC) could estimate radiation dose to tumors and healthy organs before therapy begins. Using data already available from pre-therapy PET/CT scans, this novel prediction tool could help personalize treatment plans, improve patient selection, and reduce toxicity risk.
Continue Reading this article here
